Compare BEEM & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | VERU |
|---|---|---|
| Founded | 2006 | 1971 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 40.9M |
| IPO Year | N/A | 1996 |
| Metric | BEEM | VERU |
|---|---|---|
| Price | $1.76 | $2.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.50 | ★ $22.50 |
| AVG Volume (30 Days) | ★ 820.9K | 54.1K |
| Earning Date | 04-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,296,958.00 |
| Revenue This Year | $40.48 | N/A |
| Revenue Next Year | $32.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $0.36 |
| 52 Week High | $4.04 | $4.59 |
| Indicator | BEEM | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 48.85 | 37.44 |
| Support Level | $1.59 | $0.36 |
| Resistance Level | $2.00 | $2.67 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 36.45 | 21.21 |
Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.